Navigation Links
New England Biolabs Develops Novel Small RNA NGS Protocol: Reagents Improve Yield and Decrease Adaptor-Dimer Formation
Date:2/2/2011

IPSWICH, Mass., Feb. 2, 2011 /PRNewswire/ -- New England Biolabs has expanded its line of reagents for sample preparation upstream of next generation sequencing to include NEBNext® Small RNA Sample Prep Set 1 for sequencing on the Illumina® platforms, and NEBNext Small RNA Sample Prep Set 3 for sequencing on LIFE's SOLiD™ platform. These new products offer a new and unique protocol, which results in higher yields and lower adaptor-dimer formation, as compared to other protocols. With oligos, enzymes and buffers included, both sets provide substantial cost savings, and the master mix format streamlines the workflow by reducing the number of vials and pipetting steps required.

(Photo: http://photos.prnewswire.com/prnh/20110202/NE41303 )

(Logo: http://www.newscom.com/cgi-bin/prnh/20090921/NE79207LOGO-b)

NEBNext products are a series of highly pure and cost-effective reagents that facilitate DNA and RNA sample preparation for downstream applications, such as next generation sequencing. NEBNext reagents are available for DNA, ChIP-Seq, mRNA and small RNA sample preparation. All reagents undergo stringent quality controls and functional validation by sequencing, ensuring maximum yield, convenience and value. Available as reagent sets, master mixes or modules for the three leading next generation sequencing platforms, the full range of NEBNext reagents offer convenience and customization of workflow.

For more information, visit www.NEBNext.com.

About NEB

Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications, and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs, visit www.neb.com.

Illumina® is a registered trademark of Illumina, Inc.

SOLiD™ is a trademark of LIFE Technologies.


'/>"/>
SOURCE New England Biolabs
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New England Peptide Names Director of Chemical Development
2. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
3. New England Peptide Forms Scientific Advisory Board
4. Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine
5. New England Journal of Medicine Study Highlights Need for Rapid, PCR-based Group B Streptococcus (GBS) Testing at Time of Admission for Labor and Delivery
6. Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax
7. First U.K. Stem Cell Awareness Rally to Take Place in Manchester, England on August 9th, 2009
8. Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing
9. Wellcome Trust Sanger Institute to use NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for Next Generation Sequencing
10. Organogenesis CEO Geoff MacKay and COO / CFO Gary Gillheeney Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winners in New England
11. New England Biolabs Launches NEBNext(TM) DNA Sample Prep Master Mix Set 3 for Use with SOLiD(TM) 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... ... ACEA Biosciences, a pioneer in cell analysis instrumentation and the development of ... as the new Vice President of Global Clinical Development. With more than 15 ... will now team with Dr. Li Xu, Chief Medical Officer, and Dr. Xiao Xu, ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... science and biotechnology companies today announced it named Joan Siefert Rose as ... out of Durham, NC and will begin work immediately. , Rose most recently ...
(Date:2/28/2017)... , Feb. 28, 2017 Sangamo ... genome editing, today reported its fourth quarter and ... "Early this year we rebranded our ... clinical development of genomic therapies using our industry ... gene regulation and cell therapy," said Sandy ...
(Date:2/27/2017)... 2017 A Europe-wide survey of institutes conducted ... animals in their research treat them with due care. The survey ... analysis of the results indicates that there is a strong commitment ... into practice the principles of the 3Rs (Refine, Reduce, Replace)  ... What are the ...
Breaking Biology Technology:
(Date:2/3/2017)... A new independent identity strategy consultancy firm ... . Designed to fill a critical niche in technical ... partners Mark Crego and Janice Kephart ... identity expertise that span federal governments, the 9/11 Commission, ... combined expertise has a common theme born from a ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, ... therapies for the treatment of bacterial infections, today ... of antibacterial candidates from Pro Bono Bio Ltd ... prevalence of multi-drug resistant forms of Gram-negative bacteria.  ... Anti Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
Breaking Biology News(10 mins):